First-in-Human Study to Evaluate Safety, Tolerability, and Drug Behavior of MK-8644 in Healthy Adults and Patients With Mild to Moderate Plaque Psoriasis

What This Trial Is About

Researchers are evaluating a medicine called MK-8644 in this trial, which is the first time this drug will be given to people. The study aims to learn about the safety and how well participants tolerate MK-8644, including healthy individuals and patients with mild to moderate plaque psoriasis. This Phase 1 trial is designed to assess the drugs effects in different populations, including both Japanese and non-Japanese participants. Participants will be randomly assigned to receive either MK-8644 or a matching placebo by mouth. The drug will be given under either fasted or fed conditions depending on the assigned group. The trial includes single and multiple ascending doses, as well as evaluation of food effects and relative bioavailability. The treatment period includes monitoring up to approximately 43 days. During the study, participants will have blood samples taken at various times to measure drug levels and effects. Researchers will record any adverse events and reasons for stopping treatment. They will also monitor pharmacokinetic measures such as maximum plasma concentration and the time it takes to reach it. Participants will be observed for safety and tolerability throughout the trial, which lasts until December 2027.

A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001)